ライフサイエンスコーパス: oral drug

1 is generally ideal for once daily dosing of oral drugs.

2 inhibitors limit the use of these agents as oral drugs.

3 on and capacity for first-pass metabolism of oral drugs.

4 fer a means to increase the low and variable oral drug absorption of transporter substrates while dec

5 er (hASBT) may serve as a prodrug target for oral drug absorption.

6 ate for long-lasting maintenance as it is an oral drug, active against DLBCL that can be taken for ye

7 profile with the added advantage of being an oral drug administered at home.

8 , or any condition that could interfere with oral drug administration.

9 , or any condition that could interfere with oral drug administration.

10 77 were achieved within 0.5 to 4 hours after oral drug administration.

11 good preclinical properties suitable for an oral drug, albeit a relatively short plasma half-life.

12 testinal loops, common methods for assessing oral drug and nanoparticle absorption, we found that bot

13 e >/= 1 y, weight >/= 10 kg, ability to take oral drugs, and informed consent.

14 acts only in its unconverted form, and that oral drugs are instantaneously absorbed across the gut w

15 The majority of newly discovered oral drugs are poorly water soluble, and co-administrati

16 of identifying compounds with fully aligned oral drug attributes, "best-in-class" molecules.

17 nial activity of miltefosine (MLF), the only oral drug available for the treatment of visceral and cu

18 Miltefosine is the only oral drug available for treatment of Indian visceral lei

19 Analysis of the 1983-2002 oral drugs by therapy area shows that antiinfectives and

20 Five distinct oral drug classes are now available for the treatment of

21 Laquinimod is an oral drug currently being evaluated for the treatment of

22 Albendazole, an oral drug currently used to treat parasitic infections,

23 ically address the physiological barriers to oral drug delivery and highlight technologies that may b

24 findings indicate that nanoparticle-mediated oral drug delivery can be potentially improved with depa

25 le target for amino acid ester prodrug-based oral drug delivery enhancement strategies.

26 perspective is to describe these barriers to oral drug delivery in relation to some of the work curre

27 h lycopene may be a promising application in oral drug delivery in various indications.

28 anoparticles find intriguing applications in oral drug delivery since they present a large surface ar

29 adds to the state of the art, if used as an oral drug delivery system, is the ability to monitor the

30 nologies that may be incorporated into these oral drug delivery systems to further enhance drug uptak

31 ancer drugs, (iii) transdermal systems, (iv) oral drug delivery systems, (v) pulmonary drug delivery,

32 livery, drug delivery for localized therapy, oral drug delivery systems, and biologic drug delivery s

33 at potential as carriers for therapeutics in oral drug delivery systems.

34 particle uptake from the small intestine for oral drug delivery.

35 as not been well investigated especially for oral drug delivery.

36 of appetite, the CAFE can be used to monitor oral drug delivery.

37 nsoluble or multimeric proteins required for oral drug delivery.

38 The effect of RYGB on oral drug disposition is not well understood.

39 emonstrate that the mean property values for oral drugs do not vary substantially with respect to lau

40 re is a pressing need for an effective, safe oral drug for both stages of the disease, but this will

41 Miltefosine (MIL), the only oral drug for visceral leishmaniasis (VL), is currently

42 nous drugs for at least 10 days, followed by oral drugs for at least 12 weeks.

43 d and stabilized Gemcitabine as a successful oral drug form against Gemcitabine-resistant and other d

44 The pharmacoeconomic principles that drive oral drug formulation are discussed.

45 The oral drug FTY720 affects sphingosine-1-phosphate (S1P) s

46 ondition responds to and can be treated with oral drugs instead of insulin, which is important clinic

47 ophilicity, suggesting that this property in oral drugs is important irrespective of the drug's targe

48 the calculated physicochemical properties of oral drugs launched prior to 1983 (864 drugs) and betwee

49 known P2Y receptor antagonists, highlighting oral drug-like receptor antagonists, and considers futur

50 rties is an important, unchanging feature of oral drug molecules.

51 e in spending will require more than current oral drug parity laws, such as value-based insurance tha

52 Bioavailability of oral drugs, particularly large hydrophilic agents, is of

53 By the mid-1980s, the effective oral drug, praziquantel, replaced tartar emetic a s trea

54 ew Drug Application (ANDA) submission for ER oral drug products included adequate IVIVC data to enabl

55 In all countries, children unable to take oral drugs received prereferral rectal artesunate irresp

56 y designated sedationist nurses, who used an oral drug regimen (according to weight and age from conc

57 rapeutic effects of pyridostigmine (PYR), an oral drug stimulating the parasympathetic activity throu

58 h respect to other routes of administration, oral drugs tend to be lighter and have fewer H-bond dono

59 his is the first report describing use of an oral drug that may enhance HIV-specific CD8+ T cell func

60 ese findings are observed for all classes of oral drugs, the issue is especially critical for cancer

61 w widely accepted rule of 5 in the design of oral drugs, the physicochemical properties required for

62 prevalent neglected tropical diseases using oral drug therapy.

63 ellitus patients, a change in treatment from oral drugs to insulin was often associated with a signif

64 Use of oral drugs to provide symptomatic relief of the movement

65 ties and represent an opportunity to develop oral drugs to treat this devastating disease.

66 adequately responding to chemodenervation or oral drug treatment.

67 their global impact, and the availability of oral drug treatments is an essential step in controlling

68 can be treated simultaneously with existing oral drug treatments, facilitating effective and efficie

69 of the most prevalent diseases have existing oral drug treatments.

70 tforms designed to address these barriers to oral drug uptake.

71 The oral drug was well tolerated, and no side effects were d

72 The library of marketed oral drugs was then docked into the best-performing mode